Actualización de Trading
30 de enero de 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", la "Compañía" o el "Grupo")
Actualización de Trading
Return to profitability in H2; above expectation bottom line performance
Cambridge Cognition Holdings plc (AIM: COG), que desarrolla y comercializa soluciones digitales para evaluar la salud del cerebro, se complace en anunciar una actualización comercial para el año que finalizó el 31 de diciembre de 2023.
Key (Unaudited) highlights:
· Crecimiento de los ingresos del 7% a £13.5 millones (2022: £12.6 millones)
· Adjusted operating profit of £0.9 million in H2 (2023 H1: loss of £2.1 million)
· Adjusted operating loss of £1.2 million for the year (2022: £0.1 million profit), better than market expectations
o Full year adjusted operating loss reflects the impact of business acquisitions and difficult H1 trading conditions
· Saldo de caja de £3.2 millones a 31 de diciembre de 2023 (31 de diciembre de 2022: £8.3 millones)
2023 was a year of significant progress for the Company operationally following the acquisitions of eClinicalHealth Limited ("Clinpal") at the end of 2022 and Winterlight Labs Inc ("Winterlight") at the beginning of 2023. Both of these acquisitions have now been fully integrated into the Group and annualised cost savings in excess of £1.5 million have been realised. Leveraging the unique capabilities of the acquired businesses, the Company recently launched combined product offerings during the year including AQUA, an Automated Quality Assurance solution derived from the Winterlight platform, which strengthens the Company's product portfolio and provides additional cross-selling opportunities. This contributed to a major contract win in October 2023 for a sizeable later stage clinical trial valued at £1 million.
With revenue increasing 7% over the prior year to £13.5 million and following the comprehensive integration and re-organisation mid-year, the Company made an adjusted operating profit of £0.9 million in H2, improving the adjusted operating loss from £2.1 million in H1 to £1.2 million at the end of the year. The H2 adjusted operating profit was better than expected due to robust cost control. The contracted order book remained healthy at the end of 2023 at £17.2 million (£17.6 million at 31 December 2022), with at least £8.0 million of the current contracted order book expected to be recognised as revenue in 2024, subject to customer trial schedules.
Outlook
There has been considerable M&A activity by large pharmaceutical companies in the central nervous system ("CNS") drug development sector recently and, together with an improving global economic outlook, that is expected to prompt further investment in CNS clinical trials. The Company is focused on capitalising on this market opportunity, growing the order book and maximising the benefits of the recent acquisitions to drive sustainable profitable growth.
Matthew Stork, director ejecutivo de Cambridge Cognition, comentó:
"Despite challenging market conditions during 2023, the Company has strengthened its technology platforms and commercial offering and is positioned to capitalise on the anticipated growth in the CNS drug development market. We continue to focus on delivering profitable growth and driving success over the medium-term."
The Company will announce its preliminary results for the year ended 31 December 2023 in April 2024.
The information communicated in this announcement contains inside information for the purposes of the UK Market Abuse Regulations.
Consultas:
|
Notas a los editores
Acerca de la cognición de Cambridge
Cambridge Cognition es una empresa de tecnología que desarrolla productos de salud digital para comprender, detectar y tratar mejor las afecciones que afectan la salud del cerebro. Los productos de software de la compañía evalúan la salud cognitiva en pacientes de todo el mundo para mejorar los resultados de los ensayos clínicos, identificar y estratificar a los pacientes de manera temprana y mejorar la eficiencia global en las industrias farmacéutica y de atención médica.
Para más información visite www.cambridgecognition.com
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.